Evidence map›Paper›PMID 39548554›Full record

ArticleVirology journal2024

A humanized neutralizing antibody protects against human adenovirus type 7 infection in humanized desmoglein-2 and CD46 double-receptor transgenic mice.

Chengxing Zhou, Xiaohong Liao, Zhichao Zhou, Chuncong Mo, Yujie Yang, Hui Liao, Minglei Liu, Qiong Zhang, Qiuru Li, Xingui Tian and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chengxing ZhouDepartment of Microbiology, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China.
Xiaohong LiaoGuangzhou National Laboratory, Guangzhou, China.
Zhichao ZhouState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Chuncong MoGuangzhou National Laboratory, Guangzhou, China.
Yujie YangGuangzhou National Laboratory, Guangzhou, China.
Hui LiaoGuangzhou National Laboratory, Guangzhou, China.
Minglei LiuGuangzhou National Laboratory, Guangzhou, China.
Qiong ZhangGuangzhou National Laboratory, Guangzhou, China.
Qiuru LiGuangzhou National Laboratory, Guangzhou, China.
Xingui TianState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China. xgtian@gzhmu.edu.cn.
Rong ZhouGuangzhou National Laboratory, Guangzhou, China. zhourong@vip.163.com.
Hong CaoDepartment of Microbiology, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China. gzhcao@smu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuman adenovirus type 7 (HAdV7) has become a major public health threat due to its widespread transmission, severe associated pneumonia, and a lack of effective anti-HAdV7 drugs. The aim of the current study is to design a humanized monoclonal antibody (mAb) demonstrating efficacy against HAdV-7 infections in vitro and in vivo.

methodsThe humanized neutralizing antibody, 3G5-hu, was derived from the murine mAb 3G5. Antibody activity was evaluated using a flow cytometry-based neutralization (FCN) assay to identify humanized mAbs retaining potent neutralizing activity. Additionally, a humanized hDSG2/hCD46 dual-receptor transgenic mouse model was developed to simulate HAdV-7 infection.

resultsUsing recombinant HAdV-7 expressing enhanced green fluorescent protein and clinically isolated wild-type HAdV-7, the half-maximal effective concentration of 3G5-hu against HAdV-7 was determined to be < 30 ng/mL. Notably, 3G5-hu exhibits high specificity for the hexon protein of the HAdV-7 capsid (affinity: KD = 9.02 × 10

conclusionsThe newly designed humanized mAb 3G5-hu specifically neutralizes HAdV-7 in vitro and in vivo. 3G5-hu elicits protection against HAdV-7 infection in hDSG2/hCD46 knock-in transgenic mice. The findings of this study provide insights to guide the future development of preventative and therapeutic treatments for HAdV-7 infection.

Indexed as

Adenoviruses, HumanAdenovirus Infections, HumanAntibodies, NeutralizingAntibodies, ViralDesmoglein 2Disease Models, AnimalMembrane Cofactor ProteinMice, TransgenicAnimalsAntibodies, Monoclonal, HumanizedCapsid ProteinsHumansMiceNeutralization TestsAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntibodies, ViralCapsid ProteinsCD46 protein, humanDesmoglein 2Membrane Cofactor ProteinHuman adenovirus type 7Humanized antibodiesNeutralizing monoclonal antibodiesReceptorsTransgenic mice

Identifiers

PMID39548554
PMCPMC11568553

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.